Abstract:Healthcare‐associated infections are acquired by over 4% of hospital admissions and result in approximately $28 to $45 billion US dollars of direct hospital costs. In addition, the increased incidence of antibiotic resistance highlights the necessity to develop more effective methods of prevention and/or treatment of bacterial infection. Previous work has shown that exposure of mice to lipopolysaccharide (LPS), which mimics a bacterial infection, results in an elevation in plasma pro‐inflammatory cytokines and activation of the toll‐like receptor 4 (TLR4). Recently, it has also been demonstrated that prior exposure to a TLR4 agonist attenuated plasma pro‐inflammatory cytokine response to LPS and improved survival (i.e. endotoxin tolerance). One such TLR4 agonist is monophosphoryl lipid A (MPLA), an adjuvant designed based on the structure of LPS. When MPLA is given prior to or at the time of infection, there is not only a reduced mortality as the result of the infection but there is also a reduction in the plasma pro‐inflammatory cytokine levels compared to a vehicle prime. These investigations also revealed that prior treatment of MPLA altered the metabolic phenotype of bone‐marrow‐derived macrophages. These macrophages have elevated glycolysis, oxidative capacity, and ATP production. Infection is also associated with hyperglycemia and systemic insulin resistance and proinflammatory cytokines are thought to contribute to the insulin resistance. Thus, we hypothesized that systemic administration of MPLA would also result in improved systemic metabolism and insulin sensitivity. To test this hypothesis, we performed hyperinsulinemic (2 mU·kg−1·min−1), euglycemic clamps on chronically catheterized (carotid artery and jugular vein) wild‐type mice. Three days after catheterization, mice are injected intraperitoneally with MPLA (20 mg) or saline vehicle for 2 days. On day 5 all animals received LPS (2μg/g) and clamps were performed. 3‐3Hglucose and 14C‐2deoxyglucose were infused to assess whole body glucose flux and tissue specific glucose uptake, respectively. Administration of LPS resulted in impaired (~35%) insulin sensitivity in saline group relative to historical controls; as reflected in the decrease in glucose infusion rate (Figure 1). Surprisingly, we demonstrated that mice given MPLA injections had a further impairment in insulin sensitivity compared to saline treated mice in the presence of equivalent increases in insulin levels (Figure 2). This was reflected as decreases in glucose uptake (Rg) in multiple tissues (Figure 3), while insulin suppression of endogenous glucose production was similar. Overall, these data suggest that despite beneficial metabolic changes that occur in bone‐marrow derived macrophages upon exposure to MPLA, prior treatment with MPLA does not protect against LPS‐induced insulin resistance. In fact, MPLA amplifies the insulin resistance in LPS‐treated mice. In summary, the immunological protection conferred by the MPLA shown in previous studies did not protect the mice from the systemic insulin resistance. Therefore, therapies developed to combat bacterial infection may provide immunological protection for the patient without protecting from the comorbidity of hyperglycemia. The impact of pretreatment with MPLA or saline on glucose infusion rates (Figure 1); plasma insulin levels (Figure 2); and tissue glucose uptake (Figure 3) in mice after a LPS challenge. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Differential response induced by LPS and MPLA in immunocompetent and septic individuals

Comparative Transcriptome Profiles of Human Blood in Response to the Toll-like Receptor 4 Ligands Lipopolysaccharide and Monophosphoryl Lipid A

Specific features of human monocytes activation by monophosphoryl lipid A

MPLA inhibits release of cytotoxic mediators from human neutrophils while preserving efficient bacterial killing

Leptospiral Lipopolysaccharide-Induced Expression of Inflammatory Cytokines and Mononuclear-Mac-rophage Infiltration in Viscera of Mice with Leptospira Interrogans Infection

Sphingosine 1-Phosphate Receptor-3 Enhances Pro-Inflammatory Activity in Human Monocytes (P1384)

Comparison of host immune responses to LPS in human using an immune profiling panel, in vivo endotoxemia versus ex vivo stimulation

Correlating transcription and protein expression profiles of immune biomarkers following lipopolysaccharide exposure in lung epithelial cells

Modulation of the Lipopolysaccharide Receptor Complex (CD14, TLR4, MD-2) and Toll-Like Receptor 2 in Systemic Inflammatory Response Syndrome-Positive Patients With and Without Infection: Relationship to Tolerance

Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS

Study of Monocyte Membrane Proteome Perturbation During Lipopolysaccharide‐induced Tolerance Using Itraq‐based Quantitative Proteomic Approach

Tissue-Specific Differential Expression of Novel Genes and Long Intergenic Noncoding RNAs in Humans with Extreme Response to Evoked Endotoxemia.

Evaluating multiple signaling activities in LPS induced human peripheral blood mononuclear cells

Monocytes, Peripheral Blood Mononuclear Cells, and THP-1 Cells Exhibit Different Cytokine Expression Patterns following Stimulation with Lipopolysaccharide

Modulation Of Innate Immune Responses With Synthetic Lipid A Derivatives

Endothelial cell tolerance to lipopolysaccharide challenge is induced by monophosphoryl lipid A

Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study

Gene expression profiles of RAW264.7 macrophages stimulated with preparations of LPS differing in isolation and purity.

Inflammatory Response Influences Treatment of Localized Aggressive Periodontitis

MPLA‐induced endotoxin tolerance does not protect against LPS insulin resistance